HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $4,542,000 | -8.7% | 459,695 | +11.6% | 0.01% | -16.7% |
| Q3 2016 | $4,975,000 | +42.0% | 411,838 | +1.4% | 0.01% | +50.0% |
| Q2 2016 | $3,504,000 | -0.0% | 406,054 | +9.7% | 0.00% | -20.0% |
| Q1 2016 | $3,505,000 | -43.1% | 370,079 | +4.1% | 0.01% | -37.5% |
| Q4 2015 | $6,161,000 | +29.7% | 355,507 | +0.5% | 0.01% | +33.3% |
| Q3 2015 | $4,751,000 | -41.5% | 353,733 | -1.6% | 0.01% | -40.0% |
| Q2 2015 | $8,119,000 | +98.8% | 359,561 | +25.8% | 0.01% | +100.0% |
| Q1 2015 | $4,083,000 | +49.7% | 285,925 | +1.1% | 0.01% | +25.0% |
| Q4 2014 | $2,728,000 | +5.7% | 282,731 | -0.3% | 0.00% | 0.0% |
| Q3 2014 | $2,582,000 | -7.4% | 283,706 | +0.6% | 0.00% | 0.0% |
| Q2 2014 | $2,787,000 | -17.6% | 282,066 | +5.9% | 0.00% | -20.0% |
| Q1 2014 | $3,383,000 | -7.5% | 266,258 | +9.1% | 0.01% | 0.0% |
| Q4 2013 | $3,658,000 | +32.8% | 244,049 | -2.2% | 0.01% | 0.0% |
| Q3 2013 | $2,754,000 | +46.1% | 249,418 | +5.2% | 0.01% | +66.7% |
| Q2 2013 | $1,885,000 | – | 237,159 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |